Physician profile
Daniel Wyers
NPI 1174993653
$4,488.04
in general payments reported to CMS, 2019-2025
18 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $601 · 2022: $854 · 2023: $1,223 · 2024: $1,670 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,032.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $854.31 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $722.73 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $540.15 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $509.53 | 2022-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $381.47 | 2021-2024 | Trintellix |
| Lundbeck LLC | $301.25 | 2021-2024 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $278.67 | 2021-2024 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $235.70 | 2022-2024 | Spravato |
| Neurocrine Biosciences, INC. | $216.47 | 2022-2023 | Ingrezza |
| Vanda Pharmaceuticals INC. | $93.81 | 2022-2024 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $85.79 | 2023-2024 | Auvelity |
| Jazz Pharmaceuticals INC. | $68.20 | 2021 | |
| Sunovion Pharmaceuticals INC. | $44.96 | 2021 | |
| Tris Pharma INC | $40.38 | 2024 | Dyanavel Xr |
| Corium, LLC | $37.00 | 2024 | Azstarys |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $29.72 | 2024 | Xelstrym, Secuado |
| Teva Pharmaceuticals USA, INC. | $27.94 | 2021-2023 | Austedo |
| Bausch Health US, LLC | $19.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wyers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.